Hodgkin Lymphoma

New Protool: Nivolumab-AVD in Hodgkin Lymphoma

2023-06-24

  • Study

    Phase III, randomized, controlled study (SWOG S1826)
    Previously untreated pts were ≥12 years (y) with stage 3-4 HL
    N-AVD (n=489) vs. BV-AVD (n=487)


  • Efficacy

    1-year EFS: 91% vs 84%, HR:0.56, p=0.0019
    1-year OS: 99% vs 98%


  • Safety

    Grade≥3 AEs: Neutropenia (47% vs 25%), anemia (6% vs 9%), peripheral sensory neuropathy (1% vs 8%)


    • Journal of Clin Oncol 2023 41:17_suppl, LBA4-LBA4

    SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)

    http://doi.org/10.1200/JCO.2023.41.17_suppl.LBA4

    Reviewed by Elvin Chalabiyev, MD on Jun 24, 2023